MBRX icon

Moleculin Biotech
MBRX

Overview Fund Activity

24 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Charles Schwab
1
Charles Schwab
California
$38.8K
2
VF
2
Virtu Financial
New York
$15K
3
Citadel Advisors
3
Citadel Advisors
Florida
$17.5K
4
UBS Group
4
UBS Group
Switzerland
$11.9K
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.14M

Top Sellers

1
Jane Street
1
Jane Street
New York
$0
2
Envestnet Asset Management
2
Envestnet Asset Management
Illinois
$0
3
BlackRock
3
BlackRock
New York
$272K
4
TRCT
4
Tower Research Capital (TRC)
New York
$6K
5
Osaic Holdings
5
Osaic Holdings
Arizona
$1.35K
Name Holding Trade Value Shares
Change 		Shares
Change %
Envestnet Asset Management
26
Envestnet Asset Management
Illinois
– -$12K -732 Closed
AIP
27
Almanack Investment Partners
Pennsylvania
– -$1K -67 Closed
1
2